AU Stock MarketDetailed Quotes

TLX Telix Pharmaceuticals Ltd

Watchlist
  • 22.990
  • +0.130+0.57%
20min DelayMarket Closed Nov 8 16:00 AET
7.69BMarket Cap1436.88P/E (Static)

About Telix Pharmaceuticals Ltd Company

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Company Profile

SymbolTLX
Company NameTelix Pharmaceuticals Ltd
Founded2017
MarketASX
Employees234
Fiscal Year Ends12-31
Address55 Flemington Road Suite 401, North Melbourne
CityMelbourne
CountryAustralia
Zip Code3051
Phone+61 449148448
Share RegistryLINK MARKET SERVICES LIMITED LEVEL 12, 680 GEORGE STREET, SYDNEY, NSW, AUSTRALIA, 2000 1300 554 474

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Christian Behrenbruch, D.Phil.,J.D.
  • Director, Managing Director and Group Chief Executive Officer
  • --
  • H. Kevin McCann, A.O.,B.A.,L.L.M.
  • Non-Executive Chairman of the Board
  • --
  • Dr. Andreas Kluge, M.D.,PhD
  • Director
  • --
  • Tiffany Olson, M.B.A.
  • Independent Director
  • --
  • Jann Skinner, B.Com,F.C.A.
  • Independent Director
  • --
  • Dr. Mark Nelson, M.Phil,PhD
  • Independent Director
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
AU
Overall
Symbol
Latest Price
% Chg

No Data